Retirement Systems of Alabama cut its holdings in shares of Regeneron Pharmaceuticals Inc (NASDAQ:REGN) by 1.4% during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 35,735 shares of the biopharmaceutical company’s stock after selling 517 shares during the period. Retirement Systems of Alabama’s holdings in Regeneron Pharmaceuticals were worth $14,438,000 at the end of the most recent quarter.
A number of other hedge funds and other institutional investors have also added to or reduced their stakes in REGN. Founders Capital Management LLC bought a new position in Regeneron Pharmaceuticals in the 3rd quarter valued at $226,000. Intl Fcstone Inc. bought a new position in Regeneron Pharmaceuticals in the 2nd quarter valued at $233,000. Raymond James & Associates boosted its position in Regeneron Pharmaceuticals by 57.4% in the 2nd quarter. Raymond James & Associates now owns 81,916 shares of the biopharmaceutical company’s stock valued at $28,260,000 after buying an additional 29,864 shares during the last quarter. Signaturefd LLC boosted its position in Regeneron Pharmaceuticals by 123.8% in the 2nd quarter. Signaturefd LLC now owns 358 shares of the biopharmaceutical company’s stock valued at $124,000 after buying an additional 198 shares during the last quarter. Finally, First Trust Advisors LP boosted its position in Regeneron Pharmaceuticals by 26.9% in the 2nd quarter. First Trust Advisors LP now owns 187,988 shares of the biopharmaceutical company’s stock valued at $64,854,000 after buying an additional 39,879 shares during the last quarter. Institutional investors and hedge funds own 65.95% of the company’s stock.
A number of brokerages have commented on REGN. Cowen reiterated a “hold” rating and issued a $385.00 price objective on shares of Regeneron Pharmaceuticals in a research report on Monday, October 22nd. Cantor Fitzgerald increased their price objective on Regeneron Pharmaceuticals to $441.00 and gave the company a “neutral” rating in a research report on Monday, October 22nd. JPMorgan Chase & Co. set a $405.00 price objective on Regeneron Pharmaceuticals and gave the company a “hold” rating in a research report on Monday, October 22nd. BidaskClub upgraded Regeneron Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Friday, October 19th. Finally, Morgan Stanley increased their price objective on Regeneron Pharmaceuticals from $409.00 to $412.00 and gave the company an “equal weight” rating in a research report on Thursday, October 11th. Two analysts have rated the stock with a sell rating, sixteen have issued a hold rating and eight have assigned a buy rating to the stock. The company has a consensus rating of “Hold” and an average target price of $410.95.
NASDAQ:REGN opened at $336.18 on Tuesday. Regeneron Pharmaceuticals Inc has a 12-month low of $281.89 and a 12-month high of $432.50. The company has a debt-to-equity ratio of 0.10, a quick ratio of 2.92 and a current ratio of 3.62. The firm has a market capitalization of $36.29 billion, a PE ratio of 25.07, a P/E/G ratio of 1.13 and a beta of 1.12.
Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its quarterly earnings results on Thursday, August 2nd. The biopharmaceutical company reported $5.45 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $4.60 by $0.85. Regeneron Pharmaceuticals had a return on equity of 29.30% and a net margin of 25.65%. The business had revenue of $1.61 billion for the quarter, compared to analyst estimates of $1.56 billion. During the same period last year, the company earned $4.17 EPS. The firm’s revenue was up 9.4% on a year-over-year basis. Analysts forecast that Regeneron Pharmaceuticals Inc will post 19.31 EPS for the current fiscal year.
Regeneron Pharmaceuticals Company Profile
Regeneron Pharmaceuticals, Inc, a biopharmaceutical company, discovers, invents, develops, manufactures, and commercializes medicines for treating serious medical conditions worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema (DME); myopic choroidal neovascularization; and diabetic retinopathy in patients with DME, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion.
See Also: Penny Stocks, What You Need To Know
Receive News & Ratings for Regeneron Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.